Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jiangsu Hengrui Pharmaceuticals
Biotech
Merck KGaA drops pipeline asset from SpringWorks buyout
Merck KGaA is no longer pursuing clinical-stage candidates obtained through its acquisition of SpringWorks, which centered on approved drugs.
Will Maddox
Mar 5, 2026 4:33pm
Kailera, Hengrui to advance oral obesity drug into 2 new trials
Feb 10, 2026 9:25am
Braveheart pays $65M to challenge BMS for heart disease market
Sep 5, 2025 9:05am
GSK strengthens COPD offering via $12B biobucks Hengrui deal
Jul 28, 2025 4:36am
Hengrui's GLP-1/GIP agonist posts 18% weight loss in ph. 3 trial
Jul 15, 2025 9:17am
Merck & Co. pens $200M upfront deal for Hengrui med
Mar 25, 2025 9:10am
